96.36Open96.36Pre Close0 Volume0 Open Interest160.00Strike Price0.00Turnover68.84%IV4.68%PremiumDec 20, 2024Expiry Date84.89Intrinsic Value100Multiplier27DDays to Expiry11.47Extrinsic Value100Contract SizeAmericanOptions Type0.9912Delta0.0005Gamma2.86Leverage Ratio-0.0380Theta0.1172Rho2.84Eff Leverage0.0159Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet